GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (SGX:T14) » Definitions » Price-to-Tangible-Book

Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Price-to-Tangible-Book : 2.02 (As of May. 16, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Tianjin Pharmaceutical Da Ren Tang Group Price-to-Tangible-Book?

As of today (2024-05-16), Tianjin Pharmaceutical Da Ren Tang Group's share price is $2.40. Tianjin Pharmaceutical Da Ren Tang Group's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $1.19. Hence, Tianjin Pharmaceutical Da Ren Tang Group's Price to Tangible Book Ratio of today is 2.02.

The historical rank and industry rank for Tianjin Pharmaceutical Da Ren Tang Group's Price-to-Tangible-Book or its related term are showing as below:

SGX:T14' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.84   Med: 3.29   Max: 5.86
Current: 4.9

During the past 13 years, Tianjin Pharmaceutical Da Ren Tang Group's highest Price to Tangible Book Ratio was 5.86. The lowest was 1.84. And the median was 3.29.

SGX:T14's Price-to-Tangible-Book is ranked worse than
77.39% of 867 companies
in the Drug Manufacturers industry
Industry Median: 2.37 vs SGX:T14: 4.90

A closely related ratio is called PB Ratio. As of today, Tianjin Pharmaceutical Da Ren Tang Group's share price is $2.40. Tianjin Pharmaceutical Da Ren Tang Group's Book Value per Sharefor the quarter that ended in Mar. 2024 was $1.26. Hence, Tianjin Pharmaceutical Da Ren Tang Group's P/B Ratio of today is 1.90.


Tianjin Pharmaceutical Da Ren Tang Group Price-to-Tangible-Book Historical Data

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Pharmaceutical Da Ren Tang Group Price-to-Tangible-Book Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 0.79 0.92 0.99 1.84

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.25 1.92 1.78 1.84 1.69

Competitive Comparison of Tianjin Pharmaceutical Da Ren Tang Group's Price-to-Tangible-Book

For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianjin Pharmaceutical Da Ren Tang Group's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianjin Pharmaceutical Da Ren Tang Group's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Tianjin Pharmaceutical Da Ren Tang Group's Price-to-Tangible-Book falls into.



Tianjin Pharmaceutical Da Ren Tang Group Price-to-Tangible-Book Calculation

Tianjin Pharmaceutical Da Ren Tang Group's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=2.40/1.189
=2.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Tianjin Pharmaceutical Da Ren Tang Group Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Tianjin Pharmaceutical Da Ren Tang Group's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Business Description

Traded in Other Exchanges
Address
No. 17 Baidi Road, Zhong Xin Mansion, Nankai District, Tianjin, CHN, 300193
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.

Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Headlines

No Headlines